{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:00:17Z","timestamp":1785265217344,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.lungcan.2016.09.015","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T14:17:11Z","timestamp":1475245031000},"page":"104-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Expression of mesothelin in thymic carcinoma and its potential therapeutic significance"],"prefix":"10.1016","volume":"101","author":[{"given":"Anish","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Schrump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Venzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Liewehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.09.015_bib0005","series-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","first-page":"183","author":"Travis","year":"2015"},{"key":"10.1016\/j.lungcan.2016.09.015_bib0010","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/1097-0142(19940715)74:2<606::AID-CNCR2820740212>3.0.CO;2-T","article-title":"Thymoma. Histologic subclassification is an independent prognostic factor","volume":"74","author":"Quintanilla-Martinez","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2016.09.015_bib0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1470-2045(13)70596-5","article-title":"Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial","volume":"15","author":"Rajan","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0020","unstructured":"Howlader N., Noone A.M., Krapcho M., Garshell J., Neyman N., Altekruse S.F., Kosary C.L., Yu M., Ruhl J., Tatalovich Z., Cho H., Mariotto A., Lewis D.R., Chen H.S., Feuer E.J., Cronin K.A. (eds). SEER Cancer Statistics Review, 1975\u20132010, National Cancer Institute. Bethesda, MD, http:\/\/seer.cancer.gov\/csr\/1975_2010\/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fonc.2014.00103","article-title":"Novel biologic therapies for thymic epithelial tumors","volume":"4","author":"Chen","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0035","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0040","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","author":"Ordonez","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0045","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","author":"Ordonez","year":"2003","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of mesothelin in epithelial ovarian cancer","volume":"13","author":"Hassan","year":"2005","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0055","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.09.015_bib0060","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1535-7163.MCT-11-0454","article-title":"Mesothelin-targeted agents in clinical trials and in preclinical development","volume":"11","author":"Kelly","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0065","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S1470-2045(12)70126-2","article-title":"Immunotherapies for non-small-cell lung cancer and mesothelioma","volume":"13","author":"Thomas","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0070","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.humpath.2003.07.002","article-title":"Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma","volume":"34","author":"Pan","year":"2003","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2613.2010.00745.x","article-title":"Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma","volume":"92","author":"Khoury","year":"2011","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0080","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2016.09.015_bib0085","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2010.32.4467","article-title":"Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors","volume":"29","author":"Giaccone","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0090","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","article-title":"A phase I\/II trial of belinostat in combination with cisplatin doxorubicin, and cyclophospahmide in thymic epithelial tumors: a clinical and translational study","volume":"20","author":"Thomas","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000478-200302000-00002","article-title":"Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura","volume":"27","author":"Miettinen","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0105","first-page":"427","article-title":"A network algorithm for performing Fisher\u2019s exact test in rXc contingency tables","volume":"78","author":"Mehta","year":"1983","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0110","series-title":"Categorical Data Analysis","first-page":"79","author":"Agresti","year":"1990"},{"key":"10.1016\/j.lungcan.2016.09.015_bib0115","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjc.6604964","article-title":"High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma","volume":"100","author":"Cheng","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.09.015_bib0120","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1309\/CYJH-9RXM-P2PK-120J","article-title":"On the histologic heterogeneity of thymic epithelial neoplasms. Impact of sampling in subtyping and classification of thymomas","volume":"114","author":"Moran","year":"2000","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0130","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0135","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0140","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1535-7163.MCT-15-0693","article-title":"Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer","volume":"15","author":"Weekes","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0145","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1515\/cclm.2011.816","article-title":"Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers","volume":"50","author":"Sharon","year":"2012","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0150","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1078-0432.CCR-05-1477","article-title":"Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer","volume":"12","author":"Hassan","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0155","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1158\/1055-9965.EPI-05-0334","article-title":"Mesothelin variant 1 is released from tumor cells as a diagnostic marker","volume":"15","author":"Hellstrom","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.lungcan.2016.09.015_bib0160","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1055-9965.EPI-06-0479","article-title":"Mesothelin is shed from tumor cells","volume":"15","author":"Ho","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216304846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216304846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T18:27:44Z","timestamp":1571855264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216304846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":32,"alternative-id":["S0169500216304846"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.09.015","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of mesothelin in thymic carcinoma and its potential therapeutic significance","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}